CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Benchmarks help you measure performance. This intro explains which indices serve as benchmarks and how investors use them to compare risk and return.
20,611 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Two fast-casual leaders headline the 2026 investor debate: a Mediterranean newcomer with fast expansion and a Mexican...
Regulatory moves around AI can move crypto markets faster than a breakthrough in code. This piece explains what happe...
A clear look at how Vanguard Health Care and iShares Biotechnology compete for space in a diversified portfolio. Lear...
A new tax idea targets big oil stock buybacks, but it could create more problems than it solves. This article explain...
Colorado regulators announced a settlement with Unlock Technologies to reclassify home equity agreements as consumer ...
A modest insider sale can spark questions, but the bigger signal for investors is a company delivering solid earnings...
A single Vanguard ETF has quietly led the charge over the past ten years by keeping costs ultra-low and sticking to t...
Investors confront a Musk-power dilemma: bet on SpaceX's growth trajectory or Tesla's robotics push. This analysis br...
A market-minded investor argues the reason keep buying amazon hinges on a massive, pre-contracted AWS backlog and a r...
Investing in eVTOLs isn’t just about flight tech. The real lever could be charging infrastructure. This guide explain...
Jamie Dimon drops a bold note on AI’s real impact at JPMorgan: it’s already trimming headcount in some units, but pro...